Human Molecular Genetics, 2000, Vol. 9, No. 18 2609-2616
© 2000 Oxford University Press
Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy
Brain Research Institute and 1Institute of Neurology, University of Vienna, Spitalgasse 4, A-1090 Vienna, Austria
Inherited defects in the X-chromosomal adrenoleukodystrophy (ALD; ABCD1) gene are the genetic cause of the severe neurodegenerative disorder X-linked adrenoleukodystrophy (X-ALD). Biochemically the accumulation of very long-chain fatty acids, caused by impaired peroxisomal ß-oxidation, is the pathognomonic characteristic of the disease. Due to the X-chromosomal inheritance of X-ALD no data are available to clarify the question whether mutated adrenoleukodystrophy proteins (ALDPs) can negatively influence normal ALDP function. Here we show that restoration of ß-oxidation in X-ALD fibroblasts following transient transfection with normal ALD cDNA is more effective in ALDP-deficient fibroblasts compared with fibroblasts expressing normal amounts of mutated ALDP. Furthermore, we utilized the HeLa Tet-on system to construct a stable HeLa cell line expressing a constant level of endogenous ALDP and doxycycline-inducible levels of mutated ALDP. The induction was doxycycline dosage-dependent and the ALDP correctly localized. Interestingly, although mutated ALDP increased >6-fold in a dosage-dependent manner the total amount of ALDP (mutated and normal) remained approximately even as demonstrated by western blot and flow cytometric analyses. Thus, apparently mutated and normal ALDP compete for integration into a limited number of sites in the peroxisomal membrane. Consequently, increased amounts of mutated ALDP resulted in decreased peroxisomal ß-oxidation and accumulation of very long-chain fatty acids. These findings have direct implications on future gene therapy approaches for treatment of X-ALD, since in some patients a non-functional endogenous protein could act in a dominant negative way or displace the introduced, normal protein.
+ To whom correspondence should be addressed. Tel: +43 1 42 77 62 812; Fax: +43 1 42 77 96 28; Email: johannes.berger@univie.ac.at
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Weinhofer, S. Forss-Petter, M. Zigman, and J. Berger Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy Hum. Mol. Genet., October 15, 2002; 11(22): 2701 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. O'Neill, M. Aoki, and R. H. Brown Jr. ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN Neurology, December 11, 2001; 57(11): 1956 - 1962. [Abstract] [Full Text] [PDF]
|
|